APO Research
Talk to an analyst

APO RESEARCH · REPORT

Repurposed Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Repurposed Drugs Market Outlook and Growth Opportunities 2026

2 January 2026198 pages

Choose your research edition.

Industry ResearchRepurposed Drugs Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Repurposed Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Repurposed Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Repurposed Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Repurposed Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Repurposed Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Repurposed Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Repurposed Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Repurposed Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Repurposed Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Repurposed Drugs market include Teva, Johnson & Johnson, Novartis, Mylan, Pfizer, GSK, R-Pharma, Glenmark and Fujifilm, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Repurposed Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Repurposed Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Repurposed Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Repurposed Drugs market.

Repurposed Drugs Segment by Company

Teva

Johnson & Johnson

Novartis

Mylan

Pfizer

GSK

R-Pharma

Glenmark

Fujifilm

Dr. Reddy

ChemRar Group

Bausch Health

Repurposed Drugs Segment by Type

Generic Drugs

Clinical Trial Failed Drugs

Repurposed Drugs Segment by Application

Cardiovascular Diseases

Mental Illness

Cancer

Other

Repurposed Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Repurposed Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Repurposed Drugs key companies, revenue, market share, and recent developments.

3. To split the Repurposed Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Repurposed Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Repurposed Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Repurposed Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Repurposed Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Repurposed Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Repurposed Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Repurposed Drugs industry.

Chapter 3: Detailed analysis of Repurposed Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Repurposed Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Repurposed Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Repurposed Drugs Industry Trends Table 2. Repurposed Drugs Industry Drivers Table 3. Repurposed Drugs Industry Opportunities and Challenges Table 4. Repurposed Drugs Industry Restraints Table 5. Global Repurposed Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Repurposed Drugs Revenue Share by Company (2021-2026) Table 7. Global Repurposed Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Repurposed Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Repurposed Drugs Company, Product Type & Application Table 10. Global Repurposed Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Repurposed Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Generic Drugs Table 15. Significant Companies of Clinical Trial Failed Drugs Table 16. Global Repurposed Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Repurposed Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Repurposed Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Repurposed Drugs Sales Value Share by Type (2021-2026) Table 20. Global Repurposed Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Cardiovascular Diseases Table 22. Significant Companies of Mental Illness Table 23. Significant Companies of Cancer Table 24. Significant Companies of Other Table 25. Global Repurposed Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Repurposed Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Repurposed Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Repurposed Drugs Sales Value Share by Application (2021-2026) Table 29. Global Repurposed Drugs Sales Value Share by Application (2027-2032) Table 30. Global Repurposed Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Repurposed Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Repurposed Drugs Sales Value Share by Region (2021-2026) Table 33. Global Repurposed Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Repurposed Drugs Sales Value Share by Region (2027-2032) Table 35. Global Repurposed Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Repurposed Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Repurposed Drugs Sales Value Market Share by Country (2021-2026) Table 38. Global Repurposed Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Repurposed Drugs Sales Value Market Share by Country (2027-2032) Table 40. Teva Company Information Table 41. Teva Business Overview Table 42. Teva Repurposed Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Teva Repurposed Drugs Product Portfolio Table 44. Teva Recent Development Table 45. Johnson & Johnson Company Information Table 46. Johnson & Johnson Business Overview Table 47. Johnson & Johnson Repurposed Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Johnson & Johnson Repurposed Drugs Product Portfolio Table 49. Johnson & Johnson Recent Development Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis Repurposed Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Novartis Repurposed Drugs Product Portfolio Table 54. Novartis Recent Development Table 55. Mylan Company Information Table 56. Mylan Business Overview Table 57. Mylan Repurposed Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Mylan Repurposed Drugs Product Portfolio Table 59. Mylan Recent Development Table 60. Pfizer Company Information Table 61. Pfizer Business Overview Table 62. Pfizer Repurposed Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Pfizer Repurposed Drugs Product Portfolio Table 64. Pfizer Recent Development Table 65. GSK Company Information Table 66. GSK Business Overview Table 67. GSK Repurposed Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. GSK Repurposed Drugs Product Portfolio Table 69. GSK Recent Development Table 70. R-Pharma Company Information Table 71. R-Pharma Business Overview Table 72. R-Pharma Repurposed Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. R-Pharma Repurposed Drugs Product Portfolio Table 74. R-Pharma Recent Development Table 75. Glenmark Company Information Table 76. Glenmark Business Overview Table 77. Glenmark Repurposed Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Glenmark Repurposed Drugs Product Portfolio Table 79. Glenmark Recent Development Table 80. Fujifilm Company Information Table 81. Fujifilm Business Overview Table 82. Fujifilm Repurposed Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Fujifilm Repurposed Drugs Product Portfolio Table 84. Fujifilm Recent Development Table 85. Dr. Reddy Company Information Table 86. Dr. Reddy Business Overview Table 87. Dr. Reddy Repurposed Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Dr. Reddy Repurposed Drugs Product Portfolio Table 89. Dr. Reddy Recent Development Table 90. ChemRar Group Company Information Table 91. ChemRar Group Business Overview Table 92. ChemRar Group Repurposed Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. ChemRar Group Repurposed Drugs Product Portfolio Table 94. ChemRar Group Recent Development Table 95. Bausch Health Company Information Table 96. Bausch Health Business Overview Table 97. Bausch Health Repurposed Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Bausch Health Repurposed Drugs Product Portfolio Table 99. Bausch Health Recent Development Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Repurposed Drugs Product Image Figure 2. Global Repurposed Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Repurposed Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Repurposed Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Generic Drugs Image Figure 8. Clinical Trial Failed Drugs Image Figure 9. Global Repurposed Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Repurposed Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Repurposed Drugs Sales Value Share by Type (2021-2032) Figure 12. Cardiovascular Diseases Image Figure 13. Mental Illness Image Figure 14. Cancer Image Figure 15. Other Image Figure 16. Global Repurposed Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Repurposed Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Repurposed Drugs Sales Value Share by Application (2021-2032) Figure 19. Global Repurposed Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Repurposed Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Repurposed Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. North America Repurposed Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Repurposed Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Repurposed Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Repurposed Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Repurposed Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Repurposed Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. South America Repurposed Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Repurposed Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Repurposed Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Repurposed Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Repurposed Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Repurposed Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Generic Drugs
  • Clinical Trial Failed Drugs
Applications
  • Cardiovascular Diseases
  • Mental Illness
  • Cancer
  • Other
Companies covered
  • Teva
  • Johnson & Johnson
  • Novartis
  • Mylan
  • Pfizer
  • GSK
  • R-Pharma
  • Glenmark
  • Fujifilm
  • Dr. Reddy
  • ChemRar Group
  • Bausch Health

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Repurposed Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Repurposed Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Repurposed Drugs Market Dynamics
  1. 2.1 Repurposed Drugs Industry Trends
  2. 2.2 Repurposed Drugs Industry Drivers
  3. 2.3 Repurposed Drugs Industry Opportunities and Challenges
  4. 2.4 Repurposed Drugs Industry Restraints
3 Repurposed Drugs Market by Company
  1. 3.1 Global Repurposed Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Repurposed Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Repurposed Drugs Company Ranking (2024-2026)
  4. 3.4 Global Repurposed Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Repurposed Drugs Company Product Type and Application
  6. 3.6 Global Repurposed Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Repurposed Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Repurposed Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Repurposed Drugs Market by Type
  1. 4.1 Repurposed Drugs Type Introduction
  2. 4.1.1 Generic Drugs
  3. 4.1.2 Clinical Trial Failed Drugs
  4. 4.2 Global Repurposed Drugs Sales Value by Type
  5. 4.2.1 Global Repurposed Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Repurposed Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Repurposed Drugs Sales Value Share by Type (2021-2032)
5 Repurposed Drugs Market by Application
  1. 5.1 Repurposed Drugs Application Introduction
  2. 5.1.1 Cardiovascular Diseases
  3. 5.1.2 Mental Illness
  4. 5.1.3 Cancer
  5. 5.1.4 Other
  6. 5.2 Global Repurposed Drugs Sales Value by Application
  7. 5.2.1 Global Repurposed Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Repurposed Drugs Sales Value by Application (2021-2032)
  9. 5.2.3 Global Repurposed Drugs Sales Value Share by Application (2021-2032)
6 Repurposed Drugs Regional Value Analysis
  1. 6.1 Global Repurposed Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Repurposed Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Repurposed Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Repurposed Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Repurposed Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Repurposed Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Repurposed Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Repurposed Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Repurposed Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Repurposed Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Repurposed Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Repurposed Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Repurposed Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Repurposed Drugs Sales Value Share by Country, 2025 VS 2032
7 Repurposed Drugs Country-level Value Analysis
  1. 7.1 Global Repurposed Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Repurposed Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Repurposed Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Repurposed Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Repurposed Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Repurposed Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Repurposed Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Repurposed Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Repurposed Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Repurposed Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Repurposed Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Repurposed Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Repurposed Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Repurposed Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Repurposed Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Repurposed Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Repurposed Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Repurposed Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Repurposed Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Repurposed Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Repurposed Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Repurposed Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Repurposed Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Repurposed Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Repurposed Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Repurposed Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Repurposed Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Repurposed Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Repurposed Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Repurposed Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Repurposed Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Repurposed Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Repurposed Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Repurposed Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Repurposed Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Repurposed Drugs Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Repurposed Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Repurposed Drugs Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Repurposed Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Repurposed Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Repurposed Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Repurposed Drugs Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Repurposed Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Repurposed Drugs Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GSK
  32. 8.6.1 GSK Company Information
  33. 8.6.2 GSK Business Overview
  34. 8.6.3 GSK Repurposed Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GSK Repurposed Drugs Product Portfolio
  36. 8.6.5 GSK Recent Developments
  37. 8.7 R-Pharma
  38. 8.7.1 R-Pharma Company Information
  39. 8.7.2 R-Pharma Business Overview
  40. 8.7.3 R-Pharma Repurposed Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 R-Pharma Repurposed Drugs Product Portfolio
  42. 8.7.5 R-Pharma Recent Developments
  43. 8.8 Glenmark
  44. 8.8.1 Glenmark Company Information
  45. 8.8.2 Glenmark Business Overview
  46. 8.8.3 Glenmark Repurposed Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Glenmark Repurposed Drugs Product Portfolio
  48. 8.8.5 Glenmark Recent Developments
  49. 8.9 Fujifilm
  50. 8.9.1 Fujifilm Company Information
  51. 8.9.2 Fujifilm Business Overview
  52. 8.9.3 Fujifilm Repurposed Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Fujifilm Repurposed Drugs Product Portfolio
  54. 8.9.5 Fujifilm Recent Developments
  55. 8.10 Dr. Reddy
  56. 8.10.1 Dr. Reddy Company Information
  57. 8.10.2 Dr. Reddy Business Overview
  58. 8.10.3 Dr. Reddy Repurposed Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Dr. Reddy Repurposed Drugs Product Portfolio
  60. 8.10.5 Dr. Reddy Recent Developments
  61. 8.11 ChemRar Group
  62. 8.11.1 ChemRar Group Company Information
  63. 8.11.2 ChemRar Group Business Overview
  64. 8.11.3 ChemRar Group Repurposed Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 ChemRar Group Repurposed Drugs Product Portfolio
  66. 8.11.5 ChemRar Group Recent Developments
  67. 8.12 Bausch Health
  68. 8.12.1 Bausch Health Company Information
  69. 8.12.2 Bausch Health Business Overview
  70. 8.12.3 Bausch Health Repurposed Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bausch Health Repurposed Drugs Product Portfolio
  72. 8.12.5 Bausch Health Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst